Physiomics Share Discussion Threads

[the stigologist] 13/10/2020 23:17

Great sign FDA partnering with gastro M&S specialists Simulations Plus

Will they do same with Oncology M&S specialists

[albert3591] 13/10/2020 16:18

Let’s have a load of last minute sells,just to help share price down a bit.

[albert3591] 13/10/2020 15:10

Davevt....you can’t say that stiggy says 100p.I do have to say he’s been saying it for a long time,what would Rodney call him.

[hodhasharon] 13/10/2020 15:09

This looks suspiciously like a bear trap to me. I'm not going to pull the trigger at this time.

[davevt] 13/10/2020 14:56

I see the lse rampers don't think it will drop to 3p.

Watch and learn newbies.

[hodhasharon] 12/10/2020 20:08

I’ll be back in at 3-4p. Cheers Dave.

[davevt] 12/10/2020 19:52

I mean seriously, this is what pyc do at pharmaceutical exhibitions...

[davevt] 12/10/2020 19:46

3 to 4p, worth a punt

[hodhasharon] 12/10/2020 19:39

Would you invest at any level Dave?

[notknowing] 12/10/2020 15:54

I was influenced by Stig, because his research is second to none. He didn't exactly ramp this....he just provided the facts. We didn't get the share price rise of 'biblical proportions' as some promised this time......but who knows in the future.

Anywhere near 4p and I'm back in.

[albert3591] 12/10/2020 15:40

Anyone going to own up to being sucked in by stiggys crazy predictions.

[notknowing] 12/10/2020 15:30

I wouldn't 'give up', I'm sure this will come good. From my perspective there's just too many opportunities out there at the moment to have money stuck in here.

VAL, EVG, GDR, SNG....

[albert3591] 12/10/2020 15:21

Give it up mate your done.

[the stigologist] 12/10/2020 09:27

Simulations Plus is now a $1.5bn company with revenues of circa $40m p.a. (so it's trading on c.37.5x revenue)

They raised $100m for 'Strategic M&A' in August

They are not afraid to 'buy growth' whether it be revenue or employees as this acquisition in 2014 showed

Physiomics at 6x EV/Rev looks v.vulnerable


Jul 23, 2014 Press Release

Simulations Plus to Acquire Cognigen Corporation

Keywords: clinical pharmacology, model based drug development, model-based research, wholly owned subsidiary Division: Cognigen

Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has entered into an Agreement and Plan of Merger (the “AgreementR21;) with Cognigen Corporation of Buffalo, New York.

Pursuant to the Agreement, upon closing, Cognigen will become a wholly-owned subsidiary of Simulations Plus and will continue to operate under the Cognigen name. This will result in the total number of Simulations Plus employees increasing from 30 to 65, and is expected to add approximately $5 million to the revenues of the combined company in the coming fiscal year.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, Inc., said, “This is an exciting step forward for both Simulations Plus and Cognigen. Upon closing, management of the combined company will be comprised of individuals from the current management teams of Simulations Plus and Cognigen, including Ted Grasela, the current President of Cognigen. I will remain as Chairman and CEO.”

Woltosz continued, “Ted has extensive experience in modeling and simulation, clinical pharmacology, and outcomes research. Ted and his partners, Cynthia Walawander and Jill Fiedler-Kelly, have built Cognigen over more than 20 years into a profitable industry leader in high-quality analysis of clinical trial data, serving customers ranging from top-5 pharmaceutical companies to numerous mid- and smaller-size organizations. Their advanced systems and processes provide cost-effective support for model-based research and development. These systems and the work of their dedicated scientists and support staff have earned Cognigen a worldwide reputation for the quality and reliability of their work.”

Ted Grasela said, “Simulations Plus has been a pioneer in the use of modeling and simulation in pharmaceutical research and development since 1996. The company has built a comprehensive suite of software that provides best-in-class tools spanning from early discovery through preclinical and early clinical development, and on to post-patent development of generic formulations. By combining the strengths of the two companies, we will be able to better address the recent push by regulatory agencies to include more physiologically based pharmacokinetics modeling, a strength of Simulations Plus, into clinical trial analysis, a strength of Cognigen. I look forward to Walt’s continuing guidance and mentorship as we move into a new and exciting phase of our company’s growth.”

[albert3591] 10/10/2020 22:12

How long since stiggy posted anything relevant to new news.Answers on a pin head please.Just give it up suckers you’ve been done.

[notknowing] 09/10/2020 15:18

Come on Albert. I'm glad I bailed when I did....we shouldn't tease the current suffering holders.

I put my PYC funds into GDR and have recovered my losses already.

[albert3591] 09/10/2020 15:15

How many suckers now wished they had never heard of stiggy.What was the figure he teased you all with.

[albert3591] 09/10/2020 11:10

This basket case must be finished,hence the rampers have gone.They see no chance of catching out the unexpecting suckers here anymore.

[albert3591] 09/10/2020 08:56

Sells still a coming.

[albert3591] 09/10/2020 08:20

Your having a good day girls.it’s not gone down,yet.

[davevt] 08/10/2020 17:39

There is no such thing as a long tip. No share goes up in straight line so you should always move in and out.

[albert3591] 08/10/2020 17:36

Oh dear,say no more.More carnage tomorrow no doubt,come on you rampers why aren’t you saying so cheap at this price,have to buy,it would be rude not to,amongst other such rubbish talk.

[notknowing] 08/10/2020 15:31

Yes, you did call it right. If only I'd listened earlier!

Got any long tips Dave? :-) Or do you only do bashing?